- Home
- PIII vs CODX Comparison
PIII vs CODX Comparison
Compare PIII & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- CODX
- Stock Information
- Founded
- PIII 2015
- CODX 2013
- Country
- PIII United States
- CODX United States
- Employees
- PIII N/A
- CODX N/A
- Industry
- PIII Medical/Nursing Services
- CODX Medical/Dental Instruments
- Sector
- PIII Health Care
- CODX Health Care
- Exchange
- PIII Nasdaq
- CODX Nasdaq
- Market Cap
- PIII 32.2M
- CODX 23.6M
- IPO Year
- PIII N/A
- CODX 2017
- Fundamental
- Price
- PIII $0.21
- CODX $0.76
- Analyst Decision
- PIII Buy
- CODX Hold
- Analyst Count
- PIII 3
- CODX 1
- Target Price
- PIII $2.38
- CODX $1.50
- AVG Volume (30 Days)
- PIII 322.1K
- CODX 160.0K
- Earning Date
- PIII 11-12-2024
- CODX 11-07-2024
- Dividend Yield
- PIII N/A
- CODX N/A
- EPS Growth
- PIII N/A
- CODX N/A
- EPS
- PIII N/A
- CODX N/A
- Revenue
- PIII $1,476,630,000.00
- CODX $7,321,012.00
- Revenue This Year
- PIII $21.45
- CODX N/A
- Revenue Next Year
- PIII N/A
- CODX N/A
- P/E Ratio
- PIII N/A
- CODX N/A
- Revenue Growth
- PIII 25.38
- CODX 57.16
- 52 Week Low
- PIII $0.18
- CODX $0.70
- 52 Week High
- PIII $1.78
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- PIII 43.22
- CODX 31.74
- Support Level
- PIII $0.18
- CODX $0.70
- Resistance Level
- PIII $0.23
- CODX $0.78
- Average True Range (ATR)
- PIII 0.02
- CODX 0.05
- MACD
- PIII 0.00
- CODX 0.01
- Stochastic Oscillator
- PIII 47.06
- CODX 34.15
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.